Nuvectis Pharma Initiates NXP900 Phase 1a Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Nuvectis Pharma, Inc. (NASDAQ:NVCT) has initiated a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family. The study aims to evaluate the safety, tolerability and pharmacokinetic properties of NXP900 in patients with advanced solid tumors.
September 12, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nuvectis Pharma has initiated a Phase 1a clinical trial of NXP900, which could potentially lead to a new treatment for advanced solid tumors.
The initiation of the Phase 1a clinical trial for NXP900 is a significant step for Nuvectis Pharma. If successful, it could lead to a new treatment option for advanced solid tumors, which would likely increase the company's market value and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100